scholarly journals Effects of a Supervised Nordic Walking Program on Obese Adults with and without Type 2 Diabetes: The C.U.R.I.A.Mo. Centre Experience

2020 ◽  
Vol 5 (3) ◽  
pp. 62
Author(s):  
Roberto Pippi ◽  
Andrea Di Blasio ◽  
Cristina Aiello ◽  
Carmine Fanelli ◽  
Valentina Bullo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Control ◽  
Exercise Program ◽  
Medical Intervention ◽  
Nordic Walking ◽  
Vo2 Max ◽  
Obese Adults ◽  
Walking Program

Exercise is a convenient non-medical intervention, commonly recommended in metabolic syndrome and type 2 diabetes (DM2) managements. Aerobic exercise and aerobic circuit training have been shown to be able to reduce the risk of developing DM2-related complications. Growing literature proves the usefulness of Nordic walking as exercise therapy in different disease populations, therefore it has a conceivable use in DM2 management. Aims of this study were to analyze and report the effects of two different supervised exercises (gym-based exercise and Nordic walking) on anthropometric profile, blood pressure values, blood chemistry and fitness variables in obese individuals with and without DM2. In this study, 108 obese adults (aged 45–65 years), with or without DM2, were recruited and allocated into one of four subgroups: (1) Gym-based exercise program (n = 49) or (2) Nordic walking program (n = 37) for obese adults; (3) Gym-based exercise program (n = 10) or (4) Nordic walking program (n = 12) for obese adults with DM2. In all exercise subgroups, statistically significant improvements in body weight, body mass index, fat mass index, muscular flexibility and maximal oxygen uptake (VO2 max) were observed. Moreover, a higher percentage of adherence to the gym-based program compared to Nordic walking was recorded. Our findings showed that, notwithstanding the lower adherence, a supervised Nordic walk is effective as a conventional gym-based program to improve body weight control, body composition parameters, muscular flexibility and VO2 max levels in obese adults with and without type 2 diabetes.

How to Maintain a Healthy Body Weight

2006 ◽  
Vol 76 (4) ◽  
pp. 208-215 ◽  
Author(s):  
Astrup
Keyword(s):  
Physical Activity ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Body Weight ◽  
Glycemic Index ◽  
Dairy Products ◽  
Weight Control ◽  
Healthy Body Weight ◽  
Healthy Body

The epidemic of both obesity and type 2 diabetes is due to environmental factors, but the individuals developing the conditions possess a strong genetic predisposition. Observational surveys and intervention studies have shown that excess body fatness is the major environmental cause of type 2 diabetes, and that even a minor weight loss can prevent its development in high-risk subjects. Maintenance of a healthy body weight in susceptible individuals requires 45–60 minutes physical activity daily, a fat-reduced diet with plenty of fruit, vegetables, whole grain, and lean meat and dairy products, and moderate consumption of calorie containing beverages. The use of table values to predict the glycemic index of meals is of little – if any – value, and the role of a low-glycemic index diet for body weight control is controversial. The replacement of starchy carbohydrates with protein from lean meat and lean dairy products enhances satiety, and facilitate weight control. It is possible that dairy calcium also promotes weight loss, although the mechanism of action remains unclear. A weight loss of 5–10% can be induced in almost all obese patients providing treatment is offered by a professional team consisting of a physician and dieticians or nurses trained to focus on weight loss and maintenance. Whereas increasing daily physical activity and regular exercise does not significantly effect the rate of weight loss in the induction phase, it plays an important role in the weight maintenance phase due to an impact on daily energy expenditure and also to a direct enhancement of insulin sensitivity.

scholarly journals A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes

2019 ◽  
Vol 10 (2) ◽  
pp. 683-696
Author(s):  
Cheli Melzer-Cohen ◽  
Gabriel Chodick ◽  
Lise Lotte N. Husemoen ◽  
Nicolai Rhee ◽  
Varda Shalev ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Control ◽  
Database Study ◽  
Body Weight Control ◽  
Retrospective Database

scholarly journals Selected health behaviours of type 2 diabetes patients

2017 ◽  
Vol 127 (4) ◽  
pp. 155-158
Author(s):  
Wioletta Samolińska ◽  
Bożena Kiczorowska ◽  
Edyta Kowalczuk-Vasilev ◽  
Renata Klebaniuk ◽  
Ewelina Jakubczak
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Control ◽  
Age Groups ◽  
Health Behaviours ◽  
Diet Therapy ◽  
Self Monitoring ◽  
Fat Deposits ◽  
Diabetes Patients

Abstract Introduction. Type 2 diabetes is a chronic disease with an epidemic character. Its prevalence is associated with lifestyle, many environmental factors, and genetic determinants. Implementation of diet therapy is the basis for treatment of the disease. Aim. The aim of the study was to assess health behaviours and differences in these behaviours in type 2 diabetes patients taking their age into consideration. Material and methods. The questionnaire survey was carried out among 120 subjects diagnosed with type 2 diabetes. The original questionnaire comprised questions on selected pro-health behaviours, e.g. prophylactic behaviour or self-monitoring in the disease. The statistical analysis was performed on 111 properly completed surveys. The respondents were divided into three age groups: subjects under 60 (n=24), between 60 and 75 (n=64), and over 75 years old (n=23). Results. Regardless of their age, the patients with type 2 diabetes indicated mainly arteriel hypertension as a coexisting complication. The basic element of patients’ self-monitoring was checking the blood pressure and glycaemia. Half of the patients declared body weight control, however, a majority were characterised by excessive body weight and abdominal fat deposits, irrespective of their age. Walking was the most popular form of physical activity chosen by the respondents. Regardless of their age, the type 2 diabetes patients exhibited similar readiness for self-education related to their disease. Conclusions. The surveyed respondents exhibited similar behaviours undertaken to keep healthy. The increase in the regularity of doctor appointments and in the use of pharmacotherapy was closely related to age of the respondents. The advanced age of the respondents had an impact on the regularity of foot inspection. Respondents over 75 years of age adhered to recommendations on the schedule of food and medicine intake, but used diet therapy less frequently.

scholarly journals The Synthesis and Evaluation of RGD−Conjugated Chitosan Gel as Daily Supplement for Body Weight Control

Materials ◽  
2021 ◽  
Vol 14 (16) ◽  
pp. 4467
Author(s):  
Wei-Yao Chen ◽  
Yu-Ting Chen ◽  
Cherng-Jyh Ke ◽  
Ching-Yun Chen ◽  
Feng-Huei Lin
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Chronic Diseases ◽  
Weight Control ◽  
Rgd Peptide ◽  
Health Food ◽  
Short Term ◽  
Body Weight Control

(1) Background: Obesity is one of the most widespread chronic diseases and increases the risk of several other chronic diseases, especially type 2 diabetes. (2) Methods: Endobarrier is a new medical device what is worn in the small intestines for the treatment of type 2 diabetes and obesity. However, given the invasive and other adverse effects of the Endobarrier, we propose the use of RGD peptide conjugated with chitosan (RC) as an alternative. (3) Results: The FTIR and NMR spectrum showed RGD peptide was successfully conjugated on chitosan and RGD−CT is retained in the small intestine even after digestion. In vitro of wst-1 and live and dead staining studies show that the RGD−CT gel is highly biocompatible and non-toxic. Rats treated with the RGD−CT gel for a short term showed significant decrease change more than 30% in body weight, while the blood and hematic biometrics were within normal values. (4) Conclusions: The RGD−CT gel is safe, suitable for the short-term, reducing visceral fat rate health food to control weight. In the future, it is expected to develop a safe, long-term effective, flexibility of use and low-side-effect anti-obesity therapy in the era of precision medicine by further modification.

scholarly journals A randomised-controlled trial of the effects of very low-carbohydrate and high-carbohydrate diets on cognitive performance in patients with type 2 diabetes

2016 ◽  
Vol 116 (10) ◽  
pp. 1745-1753 ◽  
Author(s):  
Jeannie Tay ◽  
Ian T. Zajac ◽  
Campbell H. Thompson ◽  
Natalie D. Luscombe-Marsh ◽  
Vanessa Danthiir ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Cognitive Function ◽  
Cognitive Performance ◽  
Perceptual Speed ◽  
Low Fat ◽  
Obese Adults ◽  
High Carbohydrate ◽  
Low Carbohydrate

AbstractThis study compared the longer-term effects of a very low-carbohydrate, high-fat diet with a high-carbohydrate, low-fat diet on cognitive performance in individuals with type 2 diabetes (T2D). In total, 115 obese adults with T2D (sixty-six males, BMI: 34·6 (sd 4·3) kg/m2, age: 58 (sd 7) years, HbA1c: 7·3 (sd 1·1) %, diabetes duration: 8 (sd 6) years) were randomised to consume either an energy-restricted, very low-carbohydrate, low-saturated-fat (LC) diet or an energy-matched high unrefined carbohydrate, low-fat (HC) diet with supervised aerobic/resistance exercise (60 min, 3 d/week) for 52 weeks. Body weight, HbA1c and cognitive performance assessing perceptual speed, reasoning speed, reasoning ability, working memory, verbal fluency, processing speed, short-term memory, inhibition and memory scanning speed were assessed before and after intervention. No differences in the changes in cognitive test performance scores between the diet groups were observed for any of the cognitive function outcomes assessed (P≥0·24 time×diet). Percentage reduction in body weight correlated with improvements with perceptual speed performance. In obese adults with T2D, both LC and HC weight-loss diets combined with exercise training had similar effects on cognitive performance. This suggests that an LC diet integrated within a lifestyle modification programme can be used as a strategy for weight and diabetes management without the concern of negatively affecting cognitive function.

scholarly journals Efficacy and Safety of Semaglutide in Glycemic Control and Body Weight Management Among Obese Type 2 Diabetes Patients Initiated or Switched to Semaglutide From Other GLP-1 Receptor Agonists

2021 ◽  
Author(s):  
Aki Okamoto ◽  
Hirohide Yokokawa ◽  
Tomoko Nagamine ◽  
Hiroshi Fukuda ◽  
Teruhiko Hisaoka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Weight Control ◽  
Efficacy And Safety ◽  
Albumin Creatinine Ratio ◽  
Body Weight Control

Abstract Background: Evidence of the efficacy and safety of semaglutide among patients with type 2 diabetes who were initiated on or were switched to semaglutide from other GLP-1 RAs remains limited. The objective of this study was to investigate the short-term effects of switching to semaglutide from other GLP-1 RAs.Methods: This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity. HbA1c, body weight, serum creatinine, serum uric acid, parameters of lipid metabolism, and parameters of liver function were measured before and 6 months after administration of semaglutide.Results: A total of 50 patients were registered: 21 men and 29 women, aged 51.3 years. Mean body mass index was 32.2 kg/m2, and serum C-peptide was 2.7mg/mL. After switching to semaglutide (n=43), HbA1c and body weight significantly decreased from 6.72 % to 6.22 % and from 86.5 kg to 82.7 kg, respectively. The same findings were observed in semaglutide-naïve patients (n=7). Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well, whereas serum creatinine did not change significantly. Conclusion: Semaglutide showed excellent efficacy, even in patients switched from other GLP-1 RAs. Semaglutide appears to be a promising agent for blood glucose and body weight control in obese type 2 diabetes mellitus patients and could be more potent in treating type 2 diabetes than existing GLP-1 RAs.

Persistence to Liraglutide Therapy Is Associated with Good Glycemic and Body Weight Control in Patients with Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2295-PUB
Author(s):  
CHELI MELZER COHEN ◽  
GABRIEL CHODICK ◽  
LISE LOTTE N. HUSEMOEN ◽  
NICOLAI RHEE ◽  
VARDA SHALEV ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Control ◽  
Body Weight Control

scholarly journals Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists

2021 ◽  
Author(s):  
Aki Okamoto ◽  
Hirohide Yokokawa ◽  
Tomoko Nagamine ◽  
Hiroshi Fukuda ◽  
Teruhiko Hisaoka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Weight Control ◽  
Efficacy And Safety ◽  
Control Body ◽  
Body Weight Control

Abstract Purpose Evidence of the efficacy and safety of semaglutide among patients with type 2 diabetes who were initiated on or were switched to semaglutide from other GLP-1 RAs remains limited. The objective of this study was to investigate the short-term effects of switching to semaglutide from other GLP-1 RAs. Methods This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity. HbA1c, body weight, serum creatinine, serum uric acid, parameters of lipid metabolism, and parameters of liver function were measured before and 6 months after administration of semaglutide. Results A total of 50 patients were registered in the study. After switching to semaglutide (n = 43), HbA1c and body weight significantly decreased (p < 0.01, p < 0.01), respectively. The same findings were observed in semaglutide-naïve patients (p = 0.04, p < 0.02) (n = 7). Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51). Conclusions Semaglutide showed excellent efficacy, even in patients switched from other GLP-1 RAs. Semaglutide appears to be a promising agent for blood glucose and body weight control in obese type 2 diabetes mellitus patients and could be more potent in treating type 2 diabetes than existing GLP-1 RAs.

Clinical Experience with Insulin Detemir: Results from the Bangladesh Cohort of Global A1chieve Study

2013 ◽  
Vol 3 (1) ◽  
pp. 11-18 ◽  
Author(s):  
Zafar Ahmed Latif ◽  
Md. Faruque Pathan ◽  
Md. Nazrul Islam Siddiqui ◽  
MA Mannan ◽  
SM Ashrafuzzaman ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Glycaemic Control ◽  
Insulin Therapy ◽  
Hba1c Level ◽  
Insulin Detemir ◽  
Entire Cohort ◽  
Baseline Visit ◽  
Effective Option

Objective: To present results from the Bangladesh cohort of the A1chieve study receiving insulin detemir (Levemir) ± oral anti diabetic drugs. Methods: Out of 1093 patients recruited from 49 sites in Bangladesh, 370 were initiated on insulin detemir (Levemir).Study visits were defined as baseline, interim (around 12 weeks from baseline) and final (around 24 weeks from baseline) visit. Results: Glycaemic control was poor in all the groups at baseline. In the entire cohort at 24 weeks, significant reductions from baseline were observed in mean HbA1c (from 10.0 % to 7.2%, p<0.001), FPG (from 10.5 to 6.7 mmol/L, p<0.001) and PPPG (from 15.3 to 8.9 mmol/L, p<0.001) levels. Overall 45.5% of the participants achieved target HbA1c level of < 7% after 24 weeks. The rate of all hypoglycaemic events in the entire cohort reduced from 1.34 (baseline) to 0.12 events/person year after 24 weeks of insulin detemir therapy (p<0.0001). There was no clinically relevant change in body weight in insulin naïve or prior insulin users groups after 24 weeks of insulin detemir therapy. Conclusions: The current study suggests that insulin detemir may be considered as a safe and effective option for initiating insulin therapy for type 2 diabetes in Bangladesh. Birdem Med J 2013; 3(1): 11-18 DOI: http://dx.doi.org/10.3329/birdem.v3i1.17121

Sign in / Sign up

Export Citation Format

Share Document